Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550215 | 0.99 | KAT2B (0.55) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14960166 | 0.91 | KAT2B (0.53) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11712746 | 0.90 | KAT2B (0.59) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL737318 | 0.87 | MEN1 (0.62) | KAT2BMAPTRAB9AALDH1A1MEN1 | |
| SCHEMBL23908182 | 0.82 | MEN1 (0.51) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6232184 | 0.82 | MAPT (0.68) | MAPTRAB9ASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL11715381 | 0.81 | HTT (0.60) | KAT2BMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2326316 | 0.81 | PKM (0.61) | MAPTRAB9ASMN1; SMN2SIGMAR1HRH3 | |
| SCHEMBL17678159 | 0.81 | MAPT (0.52) | MAPTRAB9ASIGMAR1HRH3HTT | |
| SCHEMBL9725493 | 0.81 | MEN1 (0.56) | MAPTSMN1; SMN2HRH3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126553-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | KAT2B 1157/4885MAPT 3458/4885NPC1 4415/4885 |
| US-20170183313-A1 | BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME | NFATC1, RORC, ICOS | KAT2B 1131/4885MAPT 3455/4885NPC1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.